The price is based on standard antibody production costs. A precise estimate will be provided after consultation for each project, considering the most efficient process.
Antibody Production Pricing Standard Antibody Production = ¥1,800,000 per antigen Provision of 1 to 5 candidate antibodies (200μg each) from which the customer can select the final antibody, provided at 1mg (Myc-His tagged, ELISA positive). Additional Sequencing = ¥50,000 per 10 clones Additional sequencing for the same antigen. *The standard price includes sequencing for 10 clones. Additional Candidate Antibodies = ¥50,000 per candidate antibody Additional candidate antibodies for customer confirmation against the same antigen (200μg each). *The standard price includes delivery of up to 5 clones. Additional Final Antibody Production = ¥70,000 per 1mg Additional production of final antibodies for the same antigen simultaneously. *The standard price includes delivery of 1 clone (1mg). *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
The listed desired selling price may be subject to change without notice. Additionally, the "desired selling price" is a reference price and does not reflect the actual selling price from retailers. The displayed price does not include consumption tax.
Price range
Delivery Time
※The shortest time from receiving the antigen is 7 weeks.
Applications/Examples of results
Antibodies produced by "Antibody Craftsman" can be used in various applications just like antibodies produced by conventional methods. Furthermore, since they are Fab antibodies, they possess properties that can provide additional advantages in certain assay systems, such as not requiring the removal of the Fc region to prevent binding to receptors or to minimize the reaction of human anti-mouse antibodies (HAMA). Additionally, tag-specific detection antibodies are very useful in many applications.
catalog（1）
Download All Catalogs
Company information
Gene Frontier has been expanding its business areas that contribute to the acceleration of biopharmaceuticals, including antibody drugs, and has been advancing the development of its unique technologies. Moving forward, we aim to accelerate our research and development and business development to achieve further growth on a global scale. We will continue to provide unique technologies and services for the development of innovative pharmaceuticals and diagnostic drugs, striving to be a trusted partner for our customers and contribute to 21st-century healthcare.
